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Abstract
Background
AXL is a receptor tyrosine kinase that has been related to kidney and vascular disorders.
Heart failure patients with reduced ejection fraction have higher AXL in serum than controls.
No information about Axl expression with HF progression is available.
Methods
Thoracic transverse aortic constriction (TAC) was successfully performed on male Wistar
rats (n = 25) with different constriction levels. Controls underwent sham surgery (n = 12).
Echocardiography measurements were performed 4–8 weeks after surgery. Collagen depo-
sition was measured with picrosirius red staining. Axl mRNA levels in left ventricle (LV), left
kidney (LK) and ascending aorta (aAo) and the LV expression of cardiac remodeling and
fibrogenic factors were quantified with real-time PCR. AXL LV protein levels were quantified
with western blot and localization was analyzed by immunohistochemistry. Soluble AXL lev-
els in plasma were assayed with ELISA.
Results
Successful TAC rats were classified into LV hypertrophy (LVH) or heart failure (HF), model-
ing the progressive cardiac changes after pressure overload. Collagen deposition was
increased only in the HF group. LV Axl mRNA levels were higher in LVH and HF than in
Sham rats, and correlated with LVHi, and hypertrophic and fibrogenic mediators. However,
no association was found with LV systolic function. AXL was expressed in LV myocytes and
other cell types. Concentration of circulating sAXL in plasma was increased in the LVH
group compared to Sham and HF rats. Axl mRNA levels were similar in all groups in the LK
and aAo.
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Conclusions
Axl expression pattern suggests a role in the early progression of LV remodeling in HF but
not in the later systolic dysfunction. The higher levels of circulating AXL found in HF patients
most probably shed from the heart.
1. Introduction
AXL is a receptor tyrosine kinase that belongs to the TAM family (Tyro3, Axl, MerTK recep-
tors). Gas6 is the only recognized Axl receptor ligand, and its binding triggers Axl oligomeriza-
tion and activation of downstream signal cascades that are involved in cancer, chronic
immune disorders and other diseases [1,2].
The Gas6/AXL axis regulates collagen deposition in different organs. Angiotensin II
(AngII), a main pro-fibrotic factor, triggers Axl expression in VSMCs in vitro [3]. In the liver,
Gas6/Axl promotes collagen deposition through modulation of the myofibroblast phenotype
of hepatic stellate cells [4,5]. In Axl(-/-) mice, CCl4-induced liver fibrogenesis was blunted in
comparison with wild type mice [5]. Soluble AXL (sAXL) increases in patients with liver cir-
rhosis [6,7], evolving as a potential biomarker for hepatopathies. Tissue-wise, AXL expression
is increased in keloid fibroblasts [8] and in lung fibroblasts in idiophatic pulmonary fibrosis
[9].
In the kidney, the receptor AXL and its ligand Gas6 have been reported to play an impor-
tant role in several types of kidney disease animal models [10]. Furthermore, increased Axl
expression has been detected in kidney samples from humans with diverse inflammatory renal
diseases while barely detectable in normal kidney [11].
Evolving evidence supports that AXL plays a role in cardiovascular diseases through modu-
lation of vascular smooth muscle cell (VSMC) phenotype [1]. AXL mediates the vascular
response to mechanical and chemical insults and hypertension [12–14] and contributes to vas-
cular calcification [15].
More recently, Axl expression in murine cardiac tissue has been demonstrated [16] and a
putative role of Axl in heart failure (HF) is under study on grounds of experimental and clini-
cal data. Gas6(-/-) mice lacking the Axl-ligand Gas6 are protected from pressure-overload left
ventricle (LV) remodeling and fibrosis, while LV remodeling was remarkably increased in
mice with Gas6 cardiac overexpression [17]. In humans, sAXL evolves as an attractive bio-
marker for HF and other cardiac conditions [18,19].
Our group previously reported higher cardiac and circulating AXL levels in HF patients
with reduced ejection fraction (HFREF) than in controls, and sAXL levels predicted worse HF
outcomes [20]. Nevertheless, it remains unknown the timeline of Axl expression in HF pro-
gression. In the present work, we aimed to analyze Axl expression in LV along with cardiac
remodeling progression triggered by pressure-overload in a HF animal model. We also aimed
to map the putative origin of the increased sAXL in HF patients by quantifying Axl mRNA
expression in other potential origins.
2. Methods
2.1 Thoracic transverse aortic constriction (TAC)
The experimental protocols followed the European Community Directive (2010/63/UE) and
Spanish guidelines (RD 53/2013) for the use of experimental animals and were approved by
Axl role in left ventricular remodeling
PLOS ONE | https://doi.org/10.1371/journal.pone.0217926 June 10, 2019 2 / 16
“Use of soluble form of AXL in the diagnosis and/or
prognosis of heart failure syndrome” with the
international number of publication WO 2013/
120830 A1, published on 22/08/2013. This patent
is not currently licensed to any industry and there
are no products in development or modified
products and we are not employed or receive
consultancies from industries. This patent does not
alter the authors’ adherence to PLOS ONE policies
on sharing data and materials. Also, the authors
want to share that Pablo Garcia de Frutos is
currently a PLOS ONE editor.
the Animal Research Ethics Committee of the University of Barcelona and by the Generalitat
de Catalunya (protocol number 7028).
Male wistar rats (300-350g) were purchased at Charles River (Germany) and housed at the
University of Barcelona animal facility in a controlled environment (12h of light/ 12h of dark)
and with food and water ad libitum.
Thoracic transverse aortic constriction (TAC) surgery was performed in 33 rats under sur-
gical lens. Rats were anesthesized with 2–3% inhaled isofluorane, intubated and ventilated
(CWE, Ardmore, PA, USA), and kept at 37.0±0.3˚C during the whole experiment with a
homeothermic pad (Kent Scientific, Torrington, CT, USA). Intramuscular buprenorphine
(0.03–0.05 mg/Kg) was used as analgesic. A portion of the aorta between the brachiocephalic
trunk and the left carotid artery was isolated through medial suprasternal partial thoracotomy.
A bended and blunted 18G or 20G needle was placed next to the aorta. Afterwards a piece of
5/0 nylon suture was placed and knot around both the vessel and needle to restrict blood flow.
The needle was subsequently carefully removed. Sham rats (n = 12) were littermate controls
that underwent the same surgery, but no needle and no constriction were applied. The chest
cavity and the skin were carefully closed with sutures. After recovery from anesthesia, rats
were placed back to their cages with food and water access ad libitum.
2.2 Electrocardiogram (ECG)
Four to eight weeks after surgery, a one-lead (DII) surface ECG was recorded. Rats were main-
tained at 37.0±0.3˚C with a heating pad (KentScientific, Torrington, CT, USA) under inhaled
isofluorane 1.5%. Recordings were obtained with PowerLab and Labchart v8.0 (AD Instru-
ments, Oxford, UK). ECGs were analyzed offline (Labchart v8.0, AD Instruments, Oxford,
UK) by an investigator blind to group assignment. During a stable 2-minute interval, every
two-hundred beats were averaged and semi-automatically measured. Afterwards, the ECG
parameters were manually corrected, and average results were obtained for each animal. For
each rat, heart rate (HR), RR interval, P duration, P amplitude, PR interval, QRS duration, R
amplitude, T amplitude, QT interval and Mitchell-corrected QT interval [21] were measured.
2.3 Echocardiography
Subsequent to the ECG recording, a transthoracic echocardiography was obtained under
inhaled isofluorane (2–3%). Rats were placed in a heating pad and a phased-array probe 10S
(4.5–11.5 MHz) was used attached to the Vivid system (GE Vingmed Ultrasound, Horten,
Norway). Images were analyzed using commercially available software (EchoPac v. 108.1.6,
GE Healthcare, Madrid, Spain). Left atrial and ventricle diameters, and LV functional mea-
surements were quantified in a longitudinal parasternal plane. LV diameters at both end-dias-
tole (LVEDD) and end-systole (LVESD) were measured at the level of the papillary muscles.
The posterior wall (PW) and interventricular septum (IVS) thickness were measured at end-
diastole and were indexed by the rat body weight at the sacrifice (BW). LV ejection fraction
(LVEF), fractional shortening (FS), and LV mass were estimated using previously validated
formulas in rodents [22,23].
Left ventricle mass was body weight-indexed to calculate a LV hypertrophy index (LVHi).
Two different stages of pressure-overload were identified according to echocardiographic
parameters: compensated LV hypertrophy (LVH), and overt LV systolic dysfunction and heart
failure (HF).
Because of the strain and age variability of normality values in rats, and the lack of robust
reference values in the literature, we established internally valid thresholds by characterizing
sham rats. The fractional shortening (FS) lower limit of normality was established at the lowest
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value in the sham group, and the LVHi upper limit of normality was established at the highest
value in the sham group. Sham-based thresholds are shown in the S1 Fig. Accordingly, those
rats in the TAC group with a FS<35.2% were considered to have systolic function impairment,
and those TAC rats with LVHi>3.32 g/kg were considered to have LV hypertrophy (LVH).
2.4 Euthanasia and sample collection
Rats were sacrificed with an overdose of 4–5% inhaled isoflurane. Blood samples were col-
lected with EDTA tubes and centrifuged (2000 g, 10 min at 4˚C). The supernatant was col-
lected and aliquoted. The ventricular apex was cut and fixed with formol and latter embedded
with paraffin. Left ventricle (LV) free wall, left kidney (LK) and ascending Aorta (aAo) tissues
were extracted, minced and immediately frozen with liquid nitrogen. All samples were kept at
-80˚C until RNA or protein extraction.
2.5 Fibrosis quantification
Four-micron thick sections from the apex were stained with Picrosirius-red as described in
Sanz-de la Garza et al. [24]. Six representative pictures were taken from each sample with an
Olympus BX41TF light microscope and a DP73 camera (10X objective). Relative intramyocar-
dial fibrosis was quantified blinded to group assignment, using Fiji for Windows [25]. Care
was taken to exclude perivascular and endocardial and epicardial fibrosis.
2.6 RNA isolation and real time PCR assays
Messenger RNA extraction from LV, LK and aAo was performed with Trizol Reagent (Invitro-
gen, Thermo Fisher) tissue disruption followed with silica column purification following the
mirVana miRNA Isolation Kit protocol (Invitrogen). Total RNA (1 μg for LV and LK; 0.5 μg
for aAo) was retrotranscripted with the High-Capacity cDNA Reverse Transcription Kit
(Thermo Fisher). Axl, LV remodelling and fibrosis markers mRNA levels were measured with
Real time PCR with the enzyme SYBR Select Master Mix (4472908, Thermo Fisher). Real time
PCR results were normalized to the cyclophilin B (Ppib) housekeeping gene, and presented
with the 2-ΔΔCt method.
To further explore the hypertrophic remodeling processes involved in this model, we used
the R384 “Cardiac hypertrophy” (Bio-Rad) PCR array including 96-well predesigned assays
(assayed genes in S1 Methods) for n = 10 Sham, n = 7 LVH and n = 11 HF rats. Five μg of total
RNA were retrotranscribed with the iScript cDNA Synthesis Kit (1708891, Bio-Rad). The
cDNA was diluted to a final 25 ng/μl concentration and gene expression levels were assayed
with the SsoAdvanced Universal SYBR Green Supermix (1725272, Bio-Rad) and the plates.
Cardiac hypertrophy mRNA levels were normalized to the geometric mean of Gapdh and
Hprt1, as suggested by the manufacturer. Results are shown with the 2-ΔΔCt method.
A detailed protocol is provided in the S1 Methods.
2.7 AXL protein levels quantification in plasma and cardiac tissue
Soluble AXL (sAXL) was quantified in plasma samples with the commercial ELISA Kit for
AXL Receptor Tyrosine Kinase in Rat (EKU02655, Biomatik).
Total protein extract was obtained from frozen LV samples of the Sham (n = 5), LVH
(n = 8) and HF (n = 10) groups. Thirty micrograms of total protein were run in an electropho-
resis setup, transferred onto a nitrocellulose membrane, checked by Ponceau staining, and
incubated with a primary polyclonal anti-Axl antibody (ab-72069, abcam) and a goat anti-
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rabbit secondary antibody. Bands were scanned in Image Quant LAS4000 (GE Healthcare,
OH, USA), quantified by Image Lab (Biorad) and normalized with the Ponceau staining.
A detailed protocol is provided in the S2 Methods.
2.8 Immunohistochemistry
Immunohistochemistry staining for AXL was performed in paraffin embedded apex slides by
using the polyclonal rabbit Axl antibody (PA5-23254, ThermoFisher). A detailed protocol is
provided in the S3 Methods.
2.9 Statistical analysis
Results are presented as mean±SEM or as percentages. Gaussian distribution was checked
with Q-Q plots. For mRNA, the 2-ΔΔCt results did not follow a normal distribution and a log-
transformation was applied. Comparisons between the three groups (Sham, LVH and HF)
were performed with a one-way ANOVA, followed by LSD tests in the case of a significant
omnibus test. For the PCR array, those genes in which amplification was not achieved in
>30% of samples, were excluded. Values were back-transformed to 2-ΔΔCt for visual represen-
tation. Correlations were analyzed with a Pearson test; a log-transformation was performed if
any variable was non-normally distributed.
To identify correlated (co-expressed) genes, a principal component analysis was performed.
The ΔCt value of all genes in the cardiac hypertrophy R384 array and Axl mRNA levels were
jointly analyzed. Missing values (n = 49 for the whole panel) were imputated with the pca func-
tion in R. A principal component analysis was conducted (prcomp function in R), and genes
were plotted on the basis of their two main components.
Statistical analyses were performed with Graphpad v5 (GraphPad Software, La Jolla Califor-
nia USA), SPSS v23 (IBM Corp, Armonk, NY, USA) and R v3.5.2 (R Foundation for Statistical
Computing, Vienna, Austria). A p-value <0.05 was considered to be statistically significant.
3. Results
3.1 TAC as a progressive HF model
From the 33 rats that underwent TAC surgery, eight (24%) presented a normal systolic func-
tion and normal cardiac mass. These rats were classified as non-successful TAC and excluded
from further analyses. Fourteen rats (42%) had systolic function impairment (FS<35.2%; low-
est value of sham rats) and were classified as HF rats. Eleven rats (33%) had no FS impairment
but had a LVHi>3.32 g/kg (largest value of sham rats) and were classified as LVH rats. Overall,
25 rats were classified as successful TAC into two different groups: a first stage involving LV
hypertrophy and normal systolic function, and a second stage characterized by FS impairment.
Representative LV parasternal, M-mode echocardiographic images of all groups are shown in
S2 Fig. LVHi and FS values are represented in Fig 1A and 1B.
Echocardiographic and ECG studies reflected a progressive remodeling in rats submitted to
TAC. A thicker body weight-indexed IVS was found in the LVH group compared with Sham,
in contrast to no differences for indexed PW (S1 Table). HF rats had a dilated LV (larger
LVEDDi and LVESDi, S1 Table) compared with both Sham and LVH rats. All rats had an
ECG performed before sacrifice (S2 Table). LVH and HF rats presented prolonged QT and
HR-corrected QT intervals in comparison to Sham rats. No significant differences were found
amongst groups for P wave, PR-interval, QRS duration and HR.
Collagen deposition in the ventricular apex was assessed with picrosirius red staining.
Fibrosis was similar in LVH and Sham rats, while HF rats had a remarkable ~2.5-fold increase
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(Fig 1C and 1D). The magnitude of collagen deposition correlated through an apparently
asymptotic curve with the degree of structural remodeling: fibrosis negatively correlated with
FS and positively with LVHi, LVESDi and LVEDDi (S3A Fig).
3.2 Molecular validation of different stages of pressure-overload
Consistent with HF progression, BNP mRNA levels in LV were significantly different among
the three groups largely due to a 2.5-fold increase in both TAC groups (LVH and HF) com-
pared to Sham (ANOVA, p<0.001, Fig 2A). The βMHC/αMHC ratio also differed with
increasing expression from Sham to LVH rats (4-fold) to HF rats (6-fold increase in compari-
son with Sham) (ANOVA, p<0.001, Fig 2B).
Analysis of cardiac hypertrophy related genes revealed a characteristic, progressive hyper-
trophic remodeling pattern from Sham to LVH to HF rats. The complete report of results for
all genes is provided in S3 Table. Increased LV mRNA levels of proteins involved in the IGF1
(Insulin-like growth factor 1, Fig 2C) pathway such as IGF1 receptor (p<0.05) and the Akt
(RAC-alpha serine/threonine-protein kinase) kinases (Akt1, p<0.05 and Akt2, p<0.01) were
found in LVH and HF rats compared to Sham, while Akt3 did only increased in HF rats
(p<0.05). We also found an apparent activation of downstream G protein-coupled receptors
(Fig 2D and S3 Table) pathways such as Mapk3 (Mitogen-activated protein kinase 3, p<0.01),
Camk2d and Camk2g (Calcium/calmodulin-dependent protein kinase type II subunits delta
Fig 1. Characterization of the different cardiac remodeling stages of pressure overload. (A) Left ventricular mass indexed by
the body weight (LVHi) in sham (Sham), left ventricular hypertrophy (LVH) and heart failure (HF) rats (ANOVA p< 0.001).
(B) Left ventricle fractional shortening (FS) in all groups (ANOVA p< 0.001). (C) Collagen deposition in LV apex (ANOVA
p< 0.01). (D) Representative images of picrosirius red staining of LV apex samples. ��p< 0.01 vs Sham, ���p< 0.001 vs Sham.
https://doi.org/10.1371/journal.pone.0217926.g001
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and gamma, p<0.01 in both cases), Mef2c and Mef2d (Myocyte-specific enhancer factor 2C
and 2D, p<0.01 in both cases) and Hdac5 (Histone deacetylase 5, p<0.05).
Left ventricular BNP mRNA expression correlated with all the echocardiographic measures
except for FS and LVEF (Table 1).
Fibrotic and extracellular remodeling markers Tgfβ1, Mmp2, Timp1, Col1a1, Col3a1, fibro-
nectin and vimentin demonstrated a complex balance underlying myocardial fibrosis at differ-
ent overload stages. Expression of the profibrotic Tgfβ1 cytokine and the extracellular matrix
remodeling factors Mmp2 and Timp1 were significantly increased in both LVH and HF groups
compared to Sham (S3B Fig). Col1a1 and Col3a1 mRNA levels were also different between
groups (ANOVA, p<0.01 and p<0.05, respectively), with higher values in LVH rats than in
Sham rats (S3C Fig). Differences between groups were also found with the profibrotic factors
fibronectin and vimentin (S3C Fig) with higher values in both LVH and HF than in Sham rats.
3.3 Axl expression is increased in LV in TAC animals
Left ventricular Axl mRNA levels significantly differed among the three groups (Fig 3A). Axl
expression was higher in LVH and HF rats compared with Sham animals; expression was simi-
lar in LVH and HF animals. A similar pattern was found for AXL protein levels in Western-
blot experiments, although this did not reach statistical significance (p = 0.067 for Sham vs
Fig 2. Molecular validation of different stages of LV pressure overload. (A) Messenger RNA levels in the LV of BNP (ANOVA
p<0.001). (B) β myosin heavy chain (βMHC) to α myosin heavy chain (αMHC) mRNA levels ratio in the LV (ANOVA p<0.001). (C)
Messenger RNA levels of IGF1 pathway related proteins: insulin-like growth factor 1 receptor (Igf1r) and the RAC-alpha serine/
threonine-protein kinases (Akt1, Akt2 and Akt3) (ANOVA p<0.05 for all genes). (D) Messenger RNA levels of GPCRs pathway related
proteins: mitogen-activated protein kinase 3 (Mapk3), calcium/calmodulin-dependent protein kinase type II delta subunit (Camk2d),
myocyte-specific enhancer factor 2D (Mef2d) and Histone deacetylase 5 (Hdac5) (ANOVA p<0.05 for all genes). �p< 0.05 vs Sham,
��p< 0.01 vs Sham, ���p< 0.001 vs Sham.
https://doi.org/10.1371/journal.pone.0217926.g002
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LVH) likely due to the lower sample size (S4 Fig). Axl mRNA levels positively correlated with a
deeper structural echocardiographic remodeling as assessed with LVHi (Fig 3B), but not with
systolic function (Table 1). At the molecular level, Axl mRNA levels showed a moderate, posi-
tive correlation with BNP (Fig 4A), βMHC/αMHC ratio (Fig 4B), Tgfβ1 (Fig 4C), Mmp2 (Fig
4D) and Timp1 (Fig 4E) mRNA levels. In contrast, no correlation was found between Axl and
Col1a1 (p = 0.058, R Pearson = 0.33), Col3a1 (p = 0.06, R Pearson = 0.33), fibronectin
(p = 0.47, R Pearson = 0.13) and vimentin (p = 0.10, R Pearson = 0.29) mRNA levels, and the
apex collagen percentage (p = 0.13, R Pearson = 0.35)
Table 1. Correlation of BNP and Axl mRNA levels in LV with ecocardiographic parameters.
LV-BNP (log) LV-Axl (log)
R p R p
LVHi (g/Kg) 0.62 <0.001 0.42 0.01
IVSi (mm/Kg) 0.61 <0.001 0.23 0.22
PWi (mm/Kg) 0.47 0.006 -0.13 0.48
LVEDDi (mm/Kg) 0.42 0.02 -0.06 0.76
LVESDi (mm/Kg) 0.41 0.02 0.07 0.71
FS (%) -0.31 0.08 -0.28 0.13
LVEF (%) -0.33 0.06 -0.27 0.12
LADi (mm/Kg) 0.56 0.04 -0.13 0.66
LV-BNP (log): log-transformed mRNA levels in the LV; LV-Axl (log) log-transformed mRNA levels in the LV; LVHi:
left ventricular hypertrophy index; IVSi: body weight (BW)-indexed interventricular septum thickness (IVSi); PWi
BW-indexed posterior wall indexed; LVEDDi BW-indexe left ventricle end-diastolic diameter; LVESDi: BW-indexed
left ventricle end-systolic diameter; FS: fractional shortening; LVEF: left ventricle ejection fraction; LADi: BW-
indexed left atrial diameter.
https://doi.org/10.1371/journal.pone.0217926.t001
Fig 3. Axl expression in the LV at different stages of TAC. (A) Axl left ventricle (LV) mRNA levels in all groups
(ANOVA p<0.05). (B) Linear correlation between LV logAxl mRNA levels and the LV hypertrophy index (LVHi). (C)
Representative AXL immunohistochemistry microphotographs from the LV of LVH (four upper pannels) and HF
(four lower pannels) rats. In right panels, myocytes (Myoc), inflammatory cells (Inflam), mesothelial cells (Mesot),
endothelial cells (End) and smooth muscle cells (SMC) staining are indicated with black arrows. Negative staining
controls are presented in left panels. (D) sAXL levels in plasma in all groups (ANOVA p<0.01). (E) Linear correlation
between logAxl mRNA levels in LV and sAxl in plasma. �p< 0.05 vs Sham, ��p< 0.01 vs Sham.
https://doi.org/10.1371/journal.pone.0217926.g003
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AXL protein expression in the LV localized in myocytes, inflammatory and mesothelial
cells, as well as in vascular endothelial and smooth muscle cells (Fig 3C).
Plasma concentration of soluble Axl was higher in LVH compared with Sham and HF rats
(Fig 3D). Soluble AXL yielded a moderate to good estimate of LV Axl mRNA levels (Fig 3E).
In view of the association between AXL and cardiac hypertrophy, we aimed at further
exploring Axl co-expression patterns with hypertrophic factors. Axl mRNA levels were ana-
lyzed in the context of hypertrophy mediators. A joint principal component analysis showed
that Axl expression clustered with other well-known hypertrophy factors such as Edn
(Endothelin-1), Tlr4 (Toll-like receptor 4 precursor), Cxcr4 (C-X-C chemokine receptor type
4) and Igf1 (Insulin-like growth factor I) (Fig 5).
3.4 Axl expression is not increased in LK or aAo in TAC animals
To test whether HF prompted remote changes in Axl expression, expression in the LK and
aAo was quantified. We found no differences between Sham, LVH and HF rats in either LK or
aAo (Fig 6A and 6B).
4. Discussion
This work describes for the first time changes in the LV expression of the tyrosine kinase
receptor Axl in a pressure-overload murine model. Our main findings are that (a) Axl mRNA
levels are increased in the LV of rats subjected to pressure-overload, (b) Axl expression corre-
lates with the degree of LV hypertrophy but not with systolic function impairment, (c) circulat-
ing sAXL levels estimate LV expression and are higher in plasma from LVH rats compared to
Sham and HF rats, and (d) renal and vascular Axl expression are not altered in this model.
Fig 4. Axl mRNA levels in LV correlate with remodeling factors. Linear correlation between logAxl mRNA levels and logBNP mRNA levels in
LV (A), the logRatio of β myosin heavy chain (βMHC) over α myosin heavy chain (αMHC) mRNA levels in LV (B), the logTgfβ1 mRNA levels in
LV (C), the logMmp2 mRNA levels in LV (D), the logTimp1 mRNA levels in LV (E).
https://doi.org/10.1371/journal.pone.0217926.g004
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4.1 AXL participates in pressure overload cardiac remodeling
The role of Axl in heart disease is still under debate. In transgenic mice selectively overexpres-
sing cardiac TNF-α, the expression of TAM family members Tyro3 and MerTK was up-
Fig 5. Correlation of Axl mRNA expression to hypertrophy mediators. The 2 main principal components in a PCA
analysis involving all tested genes are plotted. Axl (in blue) and cardiac remodeling factors (in red) mRNA levels.
https://doi.org/10.1371/journal.pone.0217926.g005
Axl role in left ventricular remodeling
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regulated in end-stage HF animals, while Axl and Gas6 remained unaltered; unfortunately, no
time-course experiments at earlier time points were performed [26]. Conversely, mice lacking
Gas6, the only known Axl ligand, were protected from pressure-overload and developed a
blunted hypertrophic response and dysfunction in comparison with wild-type animals [17]. In
a different setting, Zhang et al. showed that Gas6/Axl may have a protective role in a rat model
of myocardial ischemia/reperfusion injury [16].
In order to better characterize the role of AXL in HF and understand its role as a biomarker,
we studied Axl expression in rats subjected to TAC. Transverse aortic constriction is a well-
established model that mimics cardiac remodeling occurring after the instauration of LV pres-
sure-overload where different degrees of constriction trigger uneven remodeling levels.
Thereby, this model replicates the timeline stages that lead to the initial LVH and, eventually,
HF [22,27]. In the LV of TAC rats, Axl mRNA expression was increased even in the absence of
overt HF, and correlated with both BNP expression and the βMHC/αMHC ratio; the later are
standard measures of pressure-overload cardiac remodeling and dysfunction [17,27]. Never-
theless, differences between these are to be considered. BNP showed a better correlation with
systolic function than Axl, in keeping with recent clinical data [20]. The switch from a predom-
inantly alpha-MHC isoform to a predominantly beta-MHC isoform progresses from Sham to
LVH to HF rats [27], while Axl mRNA expression was similar in both TAC groups.
4.1.1 Axl and cardiac hypertrophy. In the LV of this pressure-overload model, we found
characteristic hypertrophy signatures in LVH and HF rats. Specifically, we found a progressive
(Sham to LVH to HF) activation of IGF1 and GPCRs downstream pathways (Fig 2), including
an increased expression of both endothelin receptors A and B (S3 Table). Axl mRNA expres-
sion in LV correlated with the LVHi and with well-established hypertrophy factors such as
Edn (Endothelin-1), Igf1 (Insulin-like growth factor I), Tlr4 (Toll-like receptor 4 precursor)
and Cxcr4 (C-X-C chemokine receptor type 4). In plasma, sAXL was increased only in LVH
rats but not in HF rats. All these results are concordant with a role of Axl in the early hypertro-
phic response of pressure-overload triggered cardiac remodeling, possibly substantiating the
lack of changes in late HF stages in previous works [26].
4.1.2 Axl and myocardial fibrosis. The Axl role in cardiac fibrosis is not conclusive from
our results as it is in liver [4,5] or lung [9] fibrosis. A correlation between Axl and Tgfβ1,
Mmp2 and Timp1 expression suggests that Axl has a role in early cardiac changes, but we did
not find correlation with Col1a1, Col3a1, fibronectin and vimentin mRNA levels in LV, nor
Fig 6. Axl expression in LK and aAo in the TAC model progression to HF. Ascending aorta (aAo, panel A) and left kidney (LK, panel B)
Axl mRNA levels in sham, left ventricular hypertrophy (LVH) and heart failure rats (HF).
https://doi.org/10.1371/journal.pone.0217926.g006
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with the histological fibrosis. Tgfβ1 is a key factor in pathological fibrosis and a tight relation-
ship of Axl with Tgfβ1 can be implied from the reduced expression of Tgfβ1 in Axl knockdown
[8].
The progression of heart fibrosis after acute myocardial infarction (AMI) in an early and a
late phase parallels our results. In the early phase, Tgfβ1 stimulates fibroblast chemotaxis, pro-
liferation and transformation to myofibroblast and MMPs and TIMPs expression increases.
On the contrary, collagen-I and III accumulation occurs in late fibrosis when there is replace-
ment of myocytes and scar formation [28]. Altogether, it cannot be discarded that Axl triggers
Tgfβ1 expression in the early phase and consequently the whole fibrotic cascade.
4.2 Soluble AXL as a plasmatic biomarker
Soluble AXL has been used as a plasmatic prognostic biomarker in several heart diseases and
settings. In cardiac transplant recipients, sAXL values were higher in those presenting with
adverse CV events, an association that remained significant after multivariate adjustment [18].
After an ST-elevation AMI, higher sAXL levels flag those patients who will develop HF and an
adverse LV remodeling during follow-up [19]. We have reported that sAXL is a good prognos-
tic marker of the HF major events all-cause mortality, transplantation and HF hospitalizations
at 1 year [20] and at 3.6 years follow-up [29]. The higher sAXL levels in plasma from LVH rats,
along previous clinical data [18–20,29], substantiate the use of sAXL as a plasmatic biomarker
in HF patients. In contrast with our observations that Axl may play a role in early remodeling,
sAXL was higher in patients with NYHA functional class III than II [20]. Nevertheless, func-
tional class assessment is determined by several factors beyond, and may not fully be explained
by, cardiac remodeling. Also, the heterogeneity within HF patients regarding etiology and evo-
lution time could account for the clinic-experimental differences encountered.
4.2.1 Circulating AXL may be of cardiac origin in HF patients. Axl has been involved in
remodeling processes in vessel walls and in the kidney, among others. It is therefore possible
that, in HF patients, sAXL does not reflect cardiac remodeling, but rather the co-existence of
other comorbidities or the systemic impact of HF. We therefore quantified Axl expression in
the kidney and the ascending aorta wall. On one hand, Axl has been shown to contribute to
the pathology of several glomerulonephritis and kidney conditions [10,11,30], but our results
show that Axl expression is not altered in the kidney. On the other hand, Axl has been demon-
strated to mediate VSMC migration and proliferation in vessel walls after vascular injury [31],
hypertension [32] and flow-induced vascular injury [15,31]. Due to the increased wall stretch
in the proximal side of the aortic constriction, we quantified Axl mRNA levels in aAo, where
we found a similar expression of Axl in Sham, LVH and HF rats.
In contrast, we found AXL synthesis in LV myocytes, amongst other cellular types. More-
over, there was a good correlation between cardiac Axl mRNA levels and peripheral sAXL pro-
tein. Altogether, these data support that sAXL originates from the LV of HF patients.
Nevertheless, we cannot exclude that with worsening of kidney function in later HF stages, an
sAXL increase could partially arise from a lack of renal excretion.
4.3 Limitations
Some limitations of our work should be acknowledged. First, data from animal models, in
which acute pressure overload is imposed to a previously healthy LV might not be comparable
to chronic cardiac conditions in humans. Second, up to 24% of rats submitted to TAC did not
develop signs of LVH nor of HF. In this regard, a report with mice followed with cardiac mag-
netic resonance confirmed the high variability of response to TAC; band internalization could
account for a lack of cardiac changes in some animals [33].
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5. Conclusions
Axl expression is increased in the LV of compensated and decompensated forms of pressure-
overload insults, while its expression in the kidney and ascending aorta remains unaltered.
The higher sAXL plasma levels in LVH rats and the relationship between Axl mRNA and
LVHi suggest a role of Axl in early cardiac remodeling stages. Nevertheless, further research
will be needed to gain more insight about the Axl role in the cardiac remodeling process that
leads to HF.
Supporting information
S1 Fig. Echocardiographic parameters in sham rats. (A) Frequency distribution of fractional
shortening (FS) from sham rats represented as an histogram, n (number of rats), the arrow
points to the LLN (lower limit of normality). (B) Frequency distribution of left ventricular
hypertrophy index (LVHi) from sham rats represented as an histogram, the arrow points to
the ULN (upper limit of normality).
(TIF)
S2 Fig. Representative echocardiographic recordings in all groups. Recordings obtained in
the M-mode in a parasternal longitudinal view of the LV.
(TIF)
S3 Fig. Characterization of the TAC model progression to HF. (A) Correlation between col-
lagen in apex and left ventricle fractional shortening (FS), left ventricular mass index (LVHi),
body weight (BW)-indexed left ventricular end-systolic diameter (LVESDi), and BW-indexed
left ventricular end-diastolic diameter (LVEDDi). (B) Messenger RNA levels in the LV of
Tgfβ1 (ANOVA p<0.001), Mmp2 (ANOVA p<0.01), and Timp1 (ANOVA p<0.001). (C)
Messenger RNA levels in the LV of Col1a (ANOVA, p<0.05), Col3a (ANOVA p<0.05), Fibron
(ANOVA p<0.01), and vimentin (ANOVA p<0.05). �p< 0.05 vs Sham, ��p< 0.01 vs Sham,
���p<0.001 vs Sham.
(TIF)
S4 Fig. AXL protein levels in the LV.
(TIF)
S1 Table. Echocardiographic data in all groups. LVH: left ventricular hypertrophy rats; HF:
heart failure rats; LVHi: left ventricular mass indexed by rat body weight (BW) at the sacrifice;
IVSi: BW-indexed interventricular septum thickness; PWi: BW-indexed posterior wall thick-
ness; LVEDDi: BW-indexed left ventricular end-diastolic diameter (LVEDDi); LVESDi: BW-
indexed left ventricular end-systolic diameter; FS: fractional shortening; LVEF: left ventricle
ejection fraction; LADi: BW-indexed left atrial diameter indexed. ��p<0.01 vs Sham,
���p<0.001 vs Sham, §§p<0.01 vs LVH, §§§p<0.001 vs LVH.
(DOCX)
S2 Table. ECG parameters in all groups. LVH: left ventricular hypertrophy rats; HF: heart
failure rats; bpm: beats per minute (bpm). ��p<0.01 vs Sham.
(DOCX)
S3 Table. mRNAs analyzed with the bio-rad rat cardiac hypertrophy plate. Data are pro-
vided with the 2-ΔΔCt method, where fold change in left ventricular hypertrophy rats (LVH)
and heart failure rats (HF) are compared to Sham. Whenever amplification was detected in
<70% of samples, non-applicable (NA) is reported. �p<0.05 vs Sham, ��p<0.01 vs Sham,
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S2 Methods. AXL protein levels quantification in plasma and cardiac tissue.
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5. Bárcena C, Stefanovic M, Tutusaus A, Joannas L, Menéndez A, Garcı́a-Ruiz C, et al. Gas6/Axl pathway
is activated in chronic liver disease and its targeting reduces fibrosis via hepatic stellate cell inactivation.
Supplementary data. J Hepatol. 2015; 63: 670–678. https://doi.org/10.1016/j.jhep.2015.04.013 PMID:
25908269
6. Dengler M, Staufer K, Huber H, Stauber R, Weiss KH, Starlinger P, et al. Soluble Axl is an accurate bio-
marker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter
analysis. Oncotarget. 2017; 8: 1–15. https://doi.org/10.18632/oncotarget.13926
7. Staufer K, Dengler M, Huber H, Marculescu R, Stauber R, Lackner C, et al. The non-invasive serum bio-
marker soluble Axl accurately detects advanced liver fibrosis and cirrhosis. Cell Death Dis. Nature Pub-
lishing Group; 2017; 8: e3135. https://doi.org/10.1038/cddis.2017.554 PMID: 29072690
8. Zhu HY, Bai WD, Li J, Tao K, Wang HT, Yang XK, et al. Peroxisome proliferator-activated receptor-γ
agonist troglitazone suppresses transforming growth factor-β1 signalling through miR-92b upregula-
tion-inhibited axl expression in human keloid fibroblasts in vitro. Am J Transl Res. 2016; 8: 3460–3470.
PMID: 27648136
9. Espindola MS, Habiel DM, Narayanan R, Jones I, Coelho AL, Murray LA, et al. Targeting of TAM recep-
tors ameliorates fibrotic mechanisms in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2018;
197: 1443–1456. https://doi.org/10.1164/rccm.201707-1519OC PMID: 29634284
10. Yanagita M. Gas6, warfarin, and kidney diseases. Clin Exp Nephrol. Japan; 2004; 8: 304–309. https://
doi.org/10.1007/s10157-004-0305-z PMID: 15619028
11. Fiebeler A, Park JK, Muller DN, Lindschau C, Mengel M, Merkel S, et al. Growth arrest specific protein
6/Axl signaling in human inflammatory renal diseases. Am J Kidney Dis. United States; 2004; 43: 286–
295. PMID: 14750094
12. Gerloff J, Korshunov VA. Immune modulation of vascular resident cells by Axl orchestrates carotid
intima-media thickening. Am J Pathol. Elsevier Inc.; 2012; 180: 2134–2143. https://doi.org/10.1016/j.
ajpath.2012.01.036 PMID: 22538191
13. Konishi A, Aizawa T, Mohan A, Korshunov VA, Berk BC. Hydrogen peroxide activates the Gas6-Axl
pathway in vascular smooth muscle cells. J Biol Chem. 2004; 279: 28766–28770. https://doi.org/10.
1074/jbc.M401977200 PMID: 15123721
14. Korshunov VA, Daul M, Massett MP, Berk BC. Axl mediates vascular remodeling induced by deoxycor-
ticosterone acetate-salt hypertension. Hypertension. 2007; 50: 1057–1062. https://doi.org/10.1161/
HYPERTENSIONAHA.107.096289 PMID: 17923589
15. Korshunov VA, Mohan AM, Georger MA, Berk BC. Axl, a receptor tyrosine kinase, mediates flow-
induced vascular remodeling. Circ Res. 2006; 98: 1446–1452. https://doi.org/10.1161/01.RES.
0000223322.16149.9a PMID: 16627783
16. Zhang HZ, Wu DX, Li SL, Lu XG. Protective effects of Pterostilbene against myocardial ischemia/reper-
fusion injury in rats. Inflammation. Inflammation; 2017; 40: 578–588. https://doi.org/10.1007/s10753-
016-0504-2 PMID: 28054238
17. Zhao YF, Xu DC, Zhu GF, Zhu MY, Tang K, Li WM, et al. Growth Arrest-Specific 6 Exacerbates Pres-
sure Overload-Induced Cardiac Hypertrophy. Hypertension. 2016; 67: 118–129. https://doi.org/10.
1161/HYPERTENSIONAHA.115.06254 PMID: 26573712
18. Mirabet S, Garcı́a-Osuna A, GarciaDeFrutos P, Ferrero-Gregori A, Brossa V, Lopez L, et al. High-Sen-
sitivity Troponin T and Soluble Form of AXL as Long-Term Prognostic Biomarkers after Heart Trans-
plantation. Dis Markers. 2018; 2018: 7 pages. https://doi.org/10.1155/2018/6243529 PMID: 30245754
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